Featured Studies Results

Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/328 /treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib

Clinicaltrials.gov identifier:
NCT06545942 (https://clinicaltrials.gov/show/NCT06545942)

Treatment
Treatment study for people with advanced or metastatic cancers

---

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/314 /neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer

Clinicaltrials.gov identifier:
NCT05498272 (https://clinicaltrials.gov/show/NCT05498272)

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

---

Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2

https://www.facingourrisk.org/research-clinical-trials/study/376 /using-a-parp-inhibitor-and-oral-chemotherapy-to-treat-advanced-solid-tumors-with-a-mutation-in-brca1-brca2-palb2-atm-or-chek2

Clinicaltrials.gov identifier:
NCT06177171 (https://clinicaltrials.gov/show/NCT06177171)

Treatment
Phase 1 treatment study for metastatic solid tumors

---

Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for MMR-D or MSI-H Stage IIB - III Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/358 /post-surgery-immunotherapy-toripalimab-for-mmr-d-msi-h-stage-iib-iii-colon-cancer

Clinicaltrials.gov identifier:
NCT07140679 (https://clinicaltrials.gov/show/NCT07140679)

Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer

---

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with an ATM, BRCA1/2, CHEK2, PALB2 or Other Mutation

https://www.facingourrisk.org/research-clinical-trials/study/377 /an-new-targeted-therapy-cx5461-to-treat-advanced-breast-ovarian-pancreatic-or-prostate-cancer-with-inherited-or-tumor-mutations

Clinicaltrials.gov identifier:
NCT04890613 (https://clinicaltrials.gov/show/NCT04890613)

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

---

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/344 /study-looking-at-tumor-dna-to-predict-cancer-recurrence-for-those-planning-to-undergo-chemotherapy-for-high-risk-early-breast-cancer

Clinicaltrials.gov identifier:
NCT06401421 (https://clinicaltrials.gov/show/NCT06401421)

Treatment
Biomarker study for people with early-stage breast cancer

---

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/334 /study-of-the-drug-olvi-vec-in-women-with-ovarian-cancer

Clinicaltrials.gov identifier:
NCT05281471 (https://clinicaltrials.gov/show/NCT05281471)

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

---

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents (EvoPAR-PR01)

https://www.facingourrisk.org/research-clinical-trials/study/339 /studying-the-effectiveness-of-new-parp-inhibitor-saruparib-compared-to-current-treatment-options-for-metastatic-prostate-cancer-evopar-pro1

Clinicaltrials.gov identifier:
NCT06120491 (https://clinicaltrials.gov/show/NCT06120491)

Treatment
Treatment study for metastatic, castration-sensitive prostate cancer

---

High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/294 /high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation

Clinicaltrials.gov identifier:
NCT05011383 (https://clinicaltrials.gov/show/NCT05011383)

Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation

---

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230 /treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Clinicaltrials.gov identifier:
NCT04550494 (https://clinicaltrials.gov/show/NCT04550494)

Treatment
Treatment study for people with advanced solid tumors

---

Treatment with an ATR Inhibitor for Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/157 /treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors

Clinicaltrials.gov identifier:
NCT04657068 (https://clinicaltrials.gov/show/NCT04657068)

Treatment
Advanced solid tumors

---